Sirtuin

Sirtuin (Sir2 proteins) are a class of proteins that possess either mono-ADP-ribosyltransferase, or deacylase activity, including deacetylase, desuccinylase, demalonylase, demyristoylase and depalmitoylase activity. Sirtuins regulate important biological pathways in bacteria, archaeaand eukaryotes. Sirtuins have been implicated in influencing a wide range of cellular processes like aging, transcription, apoptosis, inflammation and stress resistance, as well as energy efficiency and alertness during low-calorie situations. Sirtuins can also control circadian clocks and mitochondrial biogenesis.

(R)-Selisistat

((R)-EX-527) Cat. No.: HY-15452B

(R)-Selisistat ((R)-EX-527) is a R-enantiomer of Selisistat. Selisistat (EX-527) is a potent and selective SIRT1 inhibitor with IC_{50} of 98 nM.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(S)-Selisistat

((S)-EX-527) Cat. No.: HY-15452A

(S)-Selisistat ((S)-EX-527) is a potent and selective **SIRT1** inhibitor, with an **IC_{50}** of 98 nM.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

3-TYP

Cat. No.: HY-108331

3-TYP is a selective **SIRT3** inhibitor, with an **IC_{50}** of 16 nM, more potent over SIRT1 (**IC_{50}**=88 nM), SIRT2 (**IC_{50}**=92 nM).



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol

Cat. No.: HY-N9398

3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol, a **SIRT1** activator, exhibits significant stimulation of SIRT1 activity. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

4'-Bromo-resveratrol

(4'BR) Cat. No.: HY-124113

4'-Bromo-resveratrol is a potent and dual inhibitor **Sirtuin-1** and **Sirtuin-3**.
4'-Bromo-resveratrol inhibits melanoma cell growth through mitochondrial metabolic reprogramming.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Chloro-4-(piperazin-1-yl)quinoline

Cat. No.: HY-W020111

7-Chloro-4-(piperazin-1-yl)quinolone is an important scaffold in medicinal chemistry. 7-Chloro-4-(piperazin-1-yl)quinolone is a potent **sirtuin** inhibitor and also inhibits the **serotonin uptake** (**IC_{50}** of 50 μM).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

ADTL-SA1215

Cat. No.: HY-139742

ADTL-SA1215 is a first-in-class specific small-molecule activator of **SIRT3** that modulates autophagy in triple negative breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AGK2

Cat. No.: HY-100578

AGK2 is a selective **SIRT2** inhibitor with an **IC_{50}** of 3.5 μM. AGK2 inhibits **SIRT1** and **SIRT3** with **IC_{50}**s of 30 and 91 μM, respectively.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AGK7

(SIRT2 Inhibitor,Inactive Control) Cat. No.: HY-119857

AGK7 is a potent inhibitor of sirtuin 2 (**SIRT2**). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Agrimol B

Cat. No.: HY-N0704

Agrimol B is a polyphenol derived from Agrimonia pilosa Ledeb, suppresses adipogenesis via inducing **SIRT1** translocation and expression, and reducing **PPARγ** expression.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ainsliadimer C

Cat. No.: HY-N10125

Ainsliadimer C, a potential activator of **SIRT1**, ameliorates inflammatory responses in adipose tissue.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AK-1

Cat. No.: HY-101465

AK-1 is a potent, specific and cell-permeable **SIRT2** inhibitor, with an IC_{50} of 12.5 μM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AK-7

Cat. No.: HY-16691

AK-7 is a selective cell- and brain-permeable **SIRT2** inhibitor, with an IC_{50} of 15.5 μM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cambinol

Cat. No.: HY-100732

Cambinol is a **SIRT1** and **SIRT2** inhibitor with IC_{50} values of 56 μM and 59 μM, respectively. Cambinol is a potent brain penetrant **neutral sphingomyelinase (N-SMase)** inhibitor (exosome inhibitor).



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CAY10602

Cat. No.: HY-104073

CAY10602 is a **SIRT1** activator. CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIC35

Cat. No.: HY-111303

CHIC35, an analog of EX-527, is a potent and selective inhibitor of **SIRT1** (IC_{50}=0.124 μM). CHIC35 shows potential selective inhibition against SIRT1 over SIRT2 (IC_{50}=2.8 μM) or SIRT3 (IC_{50}>100 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dihydrocoumarin

(Hydrocoumarin; Chroman-2-one)

Cat. No.: HY-N1926

Dihydrocoumarin is a compound found in Melilotus officinalis. Dihydrocoumarin is a **yeast Sir2p** inhibitor. Dihydrocoumarin also inhibits **human SIRT1** and **SIRT2** with IC_{50}s of 208 μM and 295 μM, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Et-29

Cat. No.: HY-145651

Et-29 is a potent and selective **SIRT5** inhibitor (K_I=40 nM).



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fisetin

Cat. No.: HY-N0182

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Ganoderic acid D

Cat. No.: HY-N1511

Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of **SIRT3** and induces the deacetylated cyclophilin D (CypD) by SIRT3.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gardenia yellow

Cat. No.: HY-N6675

Gardenia yellow is an active member of crocin, increases mRNA expression of **SIRT3**, and acts as an orally active antidepressant agent.

Gardenia yellow

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Ginkgolide C

(BN-52022; Ginkgolide-C)

Cat. No.: HY-N0785

Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Inauhzin

(INZ)

Cat. No.: HY-15869

Inauhzin is a dual **SirT1/IMPDH2** inhibitor, and acts as an activator **p53**, used in the research of cancer.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JFD00244

Cat. No.: HY-108986

JFD00244 is a **sirtuin 2** (**SIRT2**) inhibitor. Anti-tumor effect.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

JGB1741

(ILS-JGB-1741)

Cat. No.: HY-111329

JGB1741 (ILS-JGB-1741) is a potent and specific **SIRT1** activity inhibitor with an IC_{50} of 15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC_{50}>100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC3482

Cat. No.: HY-112587

MC3482 is a specific sirtuin5 (**SIRT5**) inhibitor.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nicotinamide

(Niacinamide; Nicotinic acid amide)

Cat. No.: HY-B0150

Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD^+ redox homeostasis and providing NAD^+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of **SIRT1**.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Nicotinamide riboside

Cat. No.: HY-123033

Nicotinamide riboside, an orally active NAD^+ precursor, increases NAD^+ levels and activates **SIRT1** and **SIRT3**. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Nicotinamide riboside chloride

Cat. No.: HY-123033A

Nicotinamide riboside Chloride, an orally active NAD^+ precursor, increases NAD^+ levels and activates **SIRT1** and **SIRT3**.



Purity: 99.53%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

Nicotinamide riboside malate

Cat. No.: HY-123033C

Nicotinamide riboside malate, an orally active NAD^+ precursor, increases NAD^+ levels and activates **SIRT1** and **SIRT3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nicotinamide riboside tartrate

Cat. No.: HY-123033B

Nicotinamide riboside tartrate, an orally active NAD^+ precursor, increases NAD^+ levels and activates **SIRT1** and **SIRT3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nicotinamide-13C6

(Niacinamide-13C6; Nicotinic acid amide-13C6)

Cat. No.: HY-B0150S2

Nicotinamide-13C6 (Niacinamide-13C6) is the 13C-labeled Nicotinamide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ophiopogonin D'

Cat. No.: HY-N3504

Ophiopogonin D', isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C_{29} steroidal glycoside. Ophiopogonin D' shows cytotoxic activity against two human tumor cell lines MG-63 and SNU387 with IC_{50}s of 3.09 μM and 3.63 μM, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

OSS_128167

Cat. No.: HY-107454

OSS_128167 is a potent selective **sirtuin 6 (SIRT6)** inhibitor with **IC_{50}**s of 89 μM, 1578 μM and 751 μM for **SIRT6**, SIRT1 and SIRT2, respectively. OSS_128167 has anti-**HBV** activity that inhibits **HBV** transcription and replication.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC Sirt2 Degrader-1

Cat. No.: HY-103636

PROTAC Sirt2 Degrader-1 is a SirReal-based **PROTAC**, acts as a **Sirt2** degrader, composed of a highly potent and isotype-selective **Sirt2** inhibitor, a linker, and a bona fide **Cereblon** ligand for E3 ubiquitin ligase.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Resveratrol

(trans-Resveratrol; SRT501)

Cat. No.: HY-16561

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Resveratrol analog 1

Cat. No.: HY-136203

Resveratrol analog 1 is an analog of Resveratrol (HY-16561), compound 48. Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Resveratrol analog 2

Cat. No.: HY-136204

Resveratrol analog 2 is an **analog** of Resveratrol (HY-16561). Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resveratrol-13C6

(trans-Resveratrol-13C6; SRT501-13C6)

Cat. No.: HY-16561S1

Resveratrol-13C6 (trans-Resveratrol-13C6) is the 13C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resveratrol-d4

(trans-Resveratrol-d4; SRT501-d4)

Cat. No.: HY-16561S

Resveratrol-d4 (trans-Resveratrol-d4) is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salermide

Cat. No.: HY-101073

Salermide is an inhibitor of **Sirt1** and **Sirt2**; can cause strong cancer-specific apoptotic cell death.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Scopolin

Cat. No.: HY-N0341

Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots. Scopolin attenuated hepatic steatosis through activation of **SIRT1**-mediated signaling cascades.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Selisistat

(EX-527)

Cat. No.: HY-15452

Selisistat (EX-527) is a potent and selective **SirT1** (Sir2 in Drosophila melanogaster) inhibitor with an IC_{50} of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SirReal2

Cat. No.: HY-100591

SirReal2 is a potent, isotype-selective **Sirt2** inhibitor with an IC_{50} value of 140nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIRT-IN-1

Cat. No.: HY-16615

SIRT-IN-1 is a potent inhibitor of **SIRT1/2/3**, with IC_{50}**s** of 15, 10, 33 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SIRT-IN-2

Cat. No.: HY-16616

SIRT-IN-2 is a potent inhibitor of **SIRT1/2/3**, with IC_{50}**s** of 4, 4, 7 μM, respectively.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIRT-IN-3

Cat. No.: HY-133998

SIRT-IN-3 is a potent **SIRT** inhibitor, with an IC_{50} of 17 μM for SIRT1. SIRT-IN-3 shows about 4-fold and 14-fold selectivity for SIRT1 over SIRT2 and SIRT3, respectively (IC_{50} of 74 μM and 235 μM for SIRT2 and SIRT3, respectively).



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

SIRT1 activator 3

Cat. No.: HY-111317

SIRT1 activator 3 is a potent activator of **Sirt1** and suppresses TNF-α in a dose-dependent manner. SIRT1 activator 3 has the potential for anti-obesity or anti-diabetic researches.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT1-IN-1

Cat. No.: HY-136199

SIRT1-IN-1 is a selective **SIRT1** inhibitor with an IC_{50} of 0.205 μM. SIRT1-IN-1 inhibits SIRT2 with an IC_{50} of 11.5 μM. SIRT1-IN-1, a indole, is a **cytomegalovirus (CMV)** inhibitors and has antiviral activity.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SIRT1-IN-2

Cat. No.: HY-146689

SIRT1-IN-2 (compound 3h) is a potent and selective **SIRT1** (silent information regulator 1) inhibitor, with an IC_{50} of 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT1-IN-3

Cat. No.: HY-146690

SIRT1-IN-3 (compound 3j) is a potent and selective **SIRT1** inhibitor, with an IC_{50} of 4.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sirt2-IN-1

Cat. No.: HY-112427

Sirt2-IN-1 (Compound 9) is a **sirtuin 2** (**Sirt2**) inhibitor with an IC_{50} of 163 nM.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Sirt2-IN-5

Cat. No.: HY-115979

Sirt2-IN-5 is a potent **SIRT2** inhibtor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sirt2-IN-6

Cat. No.: HY-145958

Sirt2-IN-6 (compound 24a) potent and selective inhibitor of **SIRT2**, with an IC_{50} of 0.815 μM. Sirt2-IN-6 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT2-IN-8

Cat. No.: HY-107660

SIRT2-IN-8 is a potent **SIRT2** inhibitor. SIRT2-IN-8 can be used for Huntington's and Parkinson's diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT5 inhibitor 1

Cat. No.: HY-112634

SIRT5 inhibitor 1 is a potent Human **Sirtuin 5** deacylase inhibitor, with an IC_{50} of 0.11 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SIRT5 inhibitor 2

Cat. No.: HY-146386

SIRT5 inhibitor 2 (compound 49) is a potent **SIRT5** inhibitor with an IC_{50} value of 2.3 μM. SIRT5 inhibitor 2 has inhibitory activity against the SIRT5-dependent desuccinylation. SIRT5 inhibitor 2 can be used for researching cancer and neurodegenerative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT5 inhibitor 3

Cat. No.: HY-146387

SIRT5 inhibitor 3 (compound 46) is a potent and competitive **SIRT5** inhibitor with an IC_{50} value of 5.9 μM. SIRT5 inhibitor 3 can inhibit SIRT5 desuccinylation. SIRT5 inhibitor 3 can be used for researching cancer and neurodegenerative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT7 inhibitor 97491

Cat. No.: HY-135899

SIRT7 inhibitor 97491, a potent **SIRT7** inhibitor with an IC_{50} of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sirtinol

Cat. No.: HY-13515

Sirtinol is a **sirtuin (SIRT)** inhibitor, with IC_{50}s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sirtuin modulator 1

Cat. No.: HY-19758A

Sirtuin modulator 1 is a modulator of **SIRTI**, a homolog of **SIRT3**, with $EC_{1.5}$ of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SRT 1460

Cat. No.: HY-124037

SRT 1460, a potent **Sirtuin-1 (SIRT1)** activator with an $EC_{1.5}$ value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRT 1720

Cat. No.: HY-10532

SRT 1720 is a selective activator of human **SIRT1** with an $EC_{1.5}$ of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with $EC_{1.5}$s of 37 μM and > 300 μM, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SRT 1720 Hydrochloride

Cat. No.: HY-15145

SRT 1720 Hydrochloride is a selective activator of **SIRT1** with an EC_{50} of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRT 2104

Cat. No.: HY-15262

SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD^+ dependent deacetylase **Sirt1**, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington's disease.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

SRT 2183

Cat. No.: HY-19759

SRT 2183 is a selective **Sirtuin-1 (SIRT1)** activator with an $EC_{1.5}$ value of 0.36 μM. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SRT3657

Cat. No.: HY-136094

SRT3657 is a brain-permeable activator of **SIRT1**, with neuroprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SRTCX1002

Cat. No.: HY-114981

SRTCX1002 is a potent activator of **SIRT1** (STAC), suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB Activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Suramin

Cat. No.: HY-B0879

Suramin is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Suramin sodium salt

(Suramin hexasodium salt)

Cat. No.: HY-B0879A

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin sodium salt is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Tenovin-1

Cat. No.: HY-13423

Tenovin-1, a **p53** activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a **dihydroorotate dehydrogenase (DHODH)** inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tenovin-6

Cat. No.: HY-15510

Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of **p53** transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC_{50}s of 21 μM, 10 μM, and 67 μM, respectively.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tenovin-6 Hydrochloride

Cat. No.: HY-15510B

Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of **p53** transcriptional activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Thiomyristoyl

Cat. No.: HY-101278

Thiomyristoyl is a potent and specific **SIRT2** inhibitor with an **IC_{50}** of 28 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UBCS039

Cat. No.: HY-115453

UBCS039 is the first synthetic, specific **Sirtuin 6 (SIRT6)** activator, inducing autophagy in human tumor cells, with an **EC_{50}** of 38 μM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YK-3-237

Cat. No.: HY-19634

YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg